• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Down Over 1%; Crude Oil Falls Sharply

    12/6/22 12:05:03 PM ET
    $AZRE
    $BNED
    $ENIC
    $GOSS
    Electric Utilities: Central
    Utilities
    Other Specialty Stores
    Consumer Discretionary
    Get the next $AZRE alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday.

    The Dow traded down 0.74% to 33,694.46 while the NASDAQ fell 1.57% to 11,063.55. The S&P 500 also fell, dropping, 1.11% to 3,954.55.

    Also check this: Bitcoin Drops But Remains Above This Key Level; GMX Becomes Top Loser


    Leading and Lagging Sectors


    Utilities shares rose by just 0.1% on Tuesday. Meanwhile, top gainers in the sector included Enel Chile S.A. (NYSE:ENIC), up 7%, and Azure Power Global Limited (NYSE:AZRE), up 4%.


    In trading on Tuesday, communication services shares dipped by 2.3%.


    Top Headline

     

    The US trade gap increased to a four-month high of $78.2 billion in October versus a revised gao of $74.1 billion in September. Exports from the US fell by $1.9 billion to $256.6 billion in October, while imports rose by $2.2 billion to $334.8 billion in October.

     


    Equities Trading UP

     

    • Vivint Smart Home, Inc. (NYSE:VVNT) shares shot up 32% to $11.90 after NRG Energy announced it will acquire the company for $12 per share in cash.
    • Shares of Signet Jewelers Limited (NYSE:SIG) got a boost, shooting 19% to $69.01 after the company reported better-than-expected Q3 results and issued FY23 guidance above estimates.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) shares were also up, gaining 91% to $1.50 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific antibody, ivonescimab.

     

    Equities Trading DOWN

    • Gossamer Bio, Inc. (NASDAQ:GOSS) shares tumbled 73% to $2.4975 after the company reported announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).
    • Shares of MEI Pharma, Inc. (NASDAQ:MEIP) were down 31% to $0.2689 after the company announced discontinuation of zandelisib development outside of Japan following a recent FDA meeting.
    • Barnes & Noble Education, Inc. (NYSE:BNED) was down, falling 40% to $1.54 after reporting downbeat Q2 earnings.


    Also check out: Over $3 Million Bet On G-III Apparel? Check Out These 3 Stocks Insiders Are Buying


    Commodities

    In commodity news, oil traded down 2.2% to $75.27 while gold traded up 0.2% at $1,785.10.


    Silver traded down 0.1% to $22.41 on Tuesday while copper rose 0.7% to $3.8210.

     


    Euro zone


    European shares were lower today. The eurozone’s STOXX 600 fell 0.64%, London’s FTSE 100 fell 0.36% while Spain’s IBEX 35 Index fell 0.57%. The German DAX declined 0.71%, French CAC 40 fell 0.32% and Italy’s FTSE MIB Index fell 0.83%.

    The S&P Global construction PMI for the Eurozone dropped to 43.6 in November from 44.9 in the previous month, while French construction PMI declined to 40.7 in November from 44.3. The S&P Global German construction PMI declined to 41.5 from 43.8, while factory orders in Germany rose by 0.8% month-over-month during October.


    The S&P Global/CIPS construction PMI for the UK dropped to a three-month low of 50.4 for November, while retail sales in the country rose 4.1% year-over-year in November. The S&P Global Italy construction PMI rose to 52 in November from 48.1 in the previous month.

     

    Asia Pacific Markets


    Asian markets closed mixed on Tuesday, with the Japan’s Nikkei gaining 0.24% and Hong Kong’s Hang Seng Index dropping 0.40%. China’s Shanghai Composite Index rose 0.02%.

    Household spending in Japan increased by 1.2% from the previous year during October, while average cash earnings in the country climbed by 1.8% year-over-year in October.

    The Reserve Bank of Australia increased the cash rate by 25 bps to 3.1% at its recent meeting. Australia unexpectedly reported a current deficit of AUD 2.3 billion during Q3, versus market estimates of a AUD 6.2 billion surplus.

     

    Economics

     

    • The US trade gap increased to a four-month high of $78.2 billion in October versus a revised gao of $74.1 billion in September. Exports from the US fell by $1.9 billion to $256.6 billion in October, while imports rose by $2.2 billion to $334.8 billion in October.
    • The Logistics Manager’s Index declined for a second month to a reading of 53.6 in November from 57.5 in the previous month.

     

    Check out this: Investor Sentiment Drops Amid Concerns Over Further Fed Rate Increases


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 100,906,110 cases with around 1,106,990 deaths. India confirmed a total of at least 44,674,870 cases and 530,630 deaths, while France reported over 38,078,560 COVID-19 cases with 159,240 deaths. In total, there were at least 650,561,350 cases of COVID-19 worldwide with more than 6,648,270 deaths.

    Get the next $AZRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZRE
    $BNED
    $ENIC
    $GOSS

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Signet Jewelers Limited
    $SIG
    12/11/2025$96.00Neutral
    Goldman
    Signet Jewelers Limited
    $SIG
    12/3/2025$92.00 → $96.00Market Perform
    Telsey Advisory Group
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Signet Jewelers Limited
    $SIG
    11/11/2025$150.00Overweight
    Stephens
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    More analyst ratings

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Gossamer Bio with a new price target

    Barclays initiated coverage of Gossamer Bio with a rating of Overweight and set a new price target of $9.00

    1/28/26 7:16:48 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Signet Jewelers with a new price target

    Goldman initiated coverage of Signet Jewelers with a rating of Neutral and set a new price target of $96.00

    12/11/25 9:14:03 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock. Awards were made to 20 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on January 26, 2026. The options have a ten (10) year term and an exercise price of $16.56 per share, the closing price per share of the Company's common stock as reported by Nasdaq on Jan

    1/30/26 4:30:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

    BLA Filing Based on HARMONi Global Phase III Study Results PDUFA Goal Action Date of November 14, 2026 Significant Unmet Need Remains; Over 14,000 U.S. Patients Eligible for Treatment Each Year in This Setting Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA provided a Pr

    1/29/26 7:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam was granted 14,247,597 shares and bought $499,983 worth of shares (26,680 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:06:32 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    SEC Filings

    View All

    SEC Form DEF 14A filed by Barnes & Noble Education Inc

    DEF 14A - Barnes & Noble Education, Inc. (0001634117) (Filer)

    2/3/26 3:05:03 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    1/29/26 7:35:03 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Gossamer Bio Inc.

    S-3ASR - Gossamer Bio, Inc. (0001728117) (Filer)

    1/28/26 4:01:24 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Sagi Raghunandan R was granted 5,405 shares (SEC Form 4)

    4 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    1/14/26 6:02:37 PM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    SEC Form 3 filed by new insider Sagi Raghunandan R

    3 - SIGNET JEWELERS LTD (0000832988) (Issuer)

    1/14/26 6:01:21 PM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    1/12/26 4:01:39 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Leadership Updates

    Live Leadership Updates

    View All

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    IFF Appoints Virginia "Gina" Drosos to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

    6/9/25 5:46:00 PM ET
    $IFF
    $PG
    $SIG
    Major Chemicals
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary

    Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

    Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

    3/17/25 4:24:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Barnes & Noble Education Inc

    SC 13G/A - Barnes & Noble Education, Inc. (0001634117) (Subject)

    11/14/24 6:34:18 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Financials

    Live finance-specific insights

    View All

    Signet Jewelers Reports Third Quarter Fiscal 2026 Results

    Q3 Same Store Sales1 Growth of 3% Signet Jewelers Limited ("Signet" or the "Company") (NYSE:SIG) today announced its results for the 13 weeks ended November 1, 2025 ("third quarter Fiscal 2026"). "Signet's Grow Brand Love strategy delivered 3% same store sales growth led by Kay, Zales, and Jared which reflects our continued focus on our largest brands. Our balanced diamond assortment strategy, alongside ongoing stabilization in diamond retail prices, is driving growth and expanded average retails in both Bridal and Fashion," said J.K. Symancyk, Chief Executive Officer. "Looking forward, we believe we are well positioned for the holiday season with a focused assortment in key categories an

    12/2/25 6:50:00 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing

    11/5/25 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Signet Jewelers Announces Timing of Fiscal 2026 Third Quarter Earnings Release and Conference Call

    Signet Jewelers Limited (NYSE:SIG) intends to announce its third quarter results at approximately 7:00 a.m. ET on Tuesday, December 2, 2025. On that date there will be a conference call at 8:30 a.m. ET and a simultaneous audio webcast available at www.signetjewelers.com. The call details are: Toll Free – North America (+1) 800 549 8228 International All Other Location: (Toll - Local - New York) - (+1) 646 564 2877 Conference ID 37876 Registration for the listen-only webcast is available at the following link: https://events.q4inc.com/attendee/429305882 About Signet: Signet Jewelers Limited is the world's largest retailer of diamond jewelry. As a Purpose-driven and sustaina

    11/4/25 7:30:00 AM ET
    $SIG
    Consumer Specialties
    Consumer Discretionary

    $AZRE
    $BNED
    $ENIC
    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care